A 3-way cross-over, randomized, placebo-controlled, double-blind, multicenter study to assess the pharmacologic effects of a 7-day exposure to darifenacin 15 mg o.d. and tolterodine ER [extended release] 4 mg o.d on cardiovascular parameters in healthy subjects 50 years of age and older.

Trial Profile

A 3-way cross-over, randomized, placebo-controlled, double-blind, multicenter study to assess the pharmacologic effects of a 7-day exposure to darifenacin 15 mg o.d. and tolterodine ER [extended release] 4 mg o.d on cardiovascular parameters in healthy subjects 50 years of age and older.

Completed
Phase of Trial: Phase IV

Latest Information Update: 26 Oct 2007

At a glance

  • Drugs Darifenacin; Tolterodine
  • Indications Overactive bladder
  • Focus Pharmacodynamics
  • Sponsors Novartis
  • Most Recent Events

    • 26 Oct 2007 Status changed from recruiting to completed.
    • 10 Jan 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top